Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter
- ipharmaservices
- 4 days ago
- 5 min read
TOP PHARMACEUTICAL COMPANIES BY REVENUES 2025
Rank | Company | Q1 | H1 | 9M | Annual |
1 | Johnson & Johnson | $21.9 | $45.6 | $69.6 | |
2 | Roche | $18.7 | $38.3 | ||
3 | AbbVie | $13.3 | $28.7 | ||
4 | Pfizer | $13.7 | $28.4 | ||
5 | Lilly | $12.7 | $28.3 | ||
6 | AstraZeneca | $12.9 | $28.0 | ||
7 | Merck | $13.6 | $27.7 | ||
8 | Novartis | $13.2 | $27.3 | ||
9 | Novo Nordisk | $12.2 | $24.2 | ||
10 | Sanofi | $11.2 | $23.0 |
JOHNSON AND JOHNSON
Q1 REVENUES: In the first quarter of 2025, Johnson & Johnson reported revenues of $21.9 billion. The Innovative Medicine segment delivered good performance, achieving 4.2% year-over-year growth. This was primarily driven by continued strength in Oncology, led by Darzalex, Carvykti, Erleada, and Rybrevant; robust demand for Tremfya and Simponi in Immunology; and sustained momentum from Spravato in Neuroscience.
Q2 REVENUES: Johnson & Johnson reported second-quarter 2025 sales of $23.7 billion, reflecting a 5.8% year-over-year increase. Total revenues for the first half of 2025 reached $45.6 billion, with pharmaceutical sales accounting for $29.1 billion. Key growth drivers included Darzalex ($6.8 billion), Stelara ($3.3 billion), and Tremfya ($2.1 billion).
Q3 REVENUES: Johnson & Johnson reported third-quarter sales of $24 billion, marking a 6.8% increase year-over-year. Worldwide Innovative Medicine sales hit $15.6 billion, up 6.8%. MedTech sales reached $8.4 billion with a 6.8% increase. Oncology and Neuroscience drove operational gains, even as Stelara's decline due to biosimilar competition and regulatory changes tempered overall figures. Immunology and Neuroscience segments remained resilient, boosted by products like Darzalex, Erleada, Tecvayli, Talvey, Rybrevant, and Caplyta.
The total revenues in the first nine months $69.6 billion.
ROCHE
Q1 REVENUES: In the first quarter of 2025, Roche reported revenues of $18.7 billion, reflecting 6% sales growth year-over-year. The Pharmaceuticals Division led performance with an 8% increase, driven by continued strong demand for key therapies. Ocrevus remained the top revenue contributor with $2.2 billion in sales, followed by Hemlibra at $1.4 billion and Vabysmo at $1.2 billion.
Q2 REVENUES: Roche posted a 7% increase in group sales for the first half of 2025, with the pharmaceuticals Division reporting a strong 10% growth. The revenues for the first half of 2025 were $38.3 billion. Leading products included Ocrevus ($4.3 billion), Hemlibra ($3.0 billion), and Vabysmo ($2.5 billion).
Q3 REVENUES: Roche reported revenues of approximately $56.8 billion in the first nine months, reflecting a 7% increase in total sales at constant exchange rates and a 2% rise in Swiss francs (CHF).
The Pharmaceuticals Division recorded 9% growth at constant exchange rates and 4% in CHF, driven by sustained demand for its key therapies addressing serious medical conditions. Major growth drivers included Phesgo for breast cancer, Xolair for food allergies, Hemlibra for haemophilia A, Vabysmo for significant eye diseases, and Ocrevus for multiple sclerosis.
During the first nine months of the year, leading products by sales were Ocrevus (CHF 5.2 billion), Hemlibra (CHF 3.5 billion), and Vabysmo (CHF 3.0 billion).
ABBVIE
Q1 REVENUES: AbbVie delivered first-quarter 2025 net revenues of $13.343 billion, reflecting an 8.4% increase on a reported basis. The company’s global immunology portfolio generated $6.264 billion in revenue, up 16.6% year-over-year. Growth was led by Skyrizi, which reported $3.4 billion in sales, and Rinvoq, which contributed $1.7 billion.
Q2 REVENUES: AbbVie reported total revenues of $28.8 billion for the first half of 2025. The company’s top-performing products included Skyrizi ($7.8 billion), Rinvoq ($3.7 billion), and Humira ($2.3 billion).
Q3 REVENUES: AbbVie reported total net revenues of nearly $15.8 billion for the third quarter of 2025, representing a 9.1% increase on a reported basis and 8.4% growth operationally.
In the third quarter, the Immunology Portfolio generated $7.885 billion in global net revenues, with Skyrizi contributing $4.708 billion, Rinvoq $2.184 billion, and Humira $993 million.
The Oncology Portfolio totaled $1.682 billion, slightly down 0.3% reported and 1.3% operationally, including Imbruvica ($706 million), Venclexta ($726 million), and Elahere ($170 million).
The total revenues were $44.5 billion for the first nine months of 2025.
PFIZER
Q1 REVENUES: Pfizer reported first-quarter 2025 revenues of $13.7 billion, representing a decline of $1.2 billion, or 8%, compared to the same period in the prior year. Despite the overall decrease, key products continued to perform strongly, with Eliquis generating $1.9 billion in revenue, the Prevnar family contributing $1.7 billion, and the Vyndaqel family reaching $1.5 billion.
Q3 REVENUES: Pfizer reported third-quarter 2025 revenues of $16.7 billion, representing a 7% operational decline compared to the same period last year.
For the first nine months of 2025, Pfizer achieved total revenues of $45.0 billion. Major revenue contributors included the Eliquis portfolio with $5.9 billion in sales, the Prevnar vaccine family generating $4.8 billion, and Ibrance contributing $3.0 billion.
LILLY
Q3 REVENUES: Eli Lilly reported a strong third-quarter 2025 revenue of $17.6 billion, representing a 54% increase year-over-year, led by demand for its weight-loss and diabetes therapies Mounjaro and Zepbound.
The company’s revenues for the first nine months stood at $45.9 billion, reflecting sustained growth momentum across its portfolio. Key growth drivers in the first six months included $15.5 billion in revenue from Mounjaro and $9.2 billion from Zepbound, underscoring their blockbuster status in the GLP-1 drug market.
ASTRAZENECA
H1 REVENUES: AstraZeneca achieved total revenues of $28.0 billion for the first half of 2025. The company’s top revenue generators included Tagrisso ($3.5 billion), Imfinzi ($2.7 billion), Farxiga ($4.2 billion), and Symbicort ($1.4 billion).
9M REVENUES: AstraZeneca reported total revenues of $43.2 billion for the first nine months of the year, including $15.2 billion in the third quarter. Key growth drivers included Tagrisso with $5.2 billion in revenues, Imfinzi with $4.3 billion, and Farxiga with $6.3 billion.
MERCK
Q1 REVENUES: In the first quarter of 2025, Merck reported pharmaceutical revenues of $13.6 billion. The decline was primarily driven by lower sales in vaccines, virology, and immunology. This was partially offset by continued growth in oncology, cardiology, and diabetes.
Keytruda remained the company’s leading product with $7.2 billion in revenue, while Gardasil/Gardasil 9 contributed $1.3 billion.
NOVARTIS
Q1 REVENUES: In the first quarter of 2025, Novartis reported net sales of $13.2 billion, representing 12% growth year-over-year. Volume contributed 15 percentage points to this growth, underscoring strong underlying demand across key therapies. Leading the performance were Entresto with $2.2 billion in sales and Cosentyx with $1.5 billion.
Q2 REVENUES: Novartis reported net sales of $27.3 billion for the first half of 2025, reflecting an 11% year-over-year increase. Leading contributors to this performance included Entresto ($4.6 billion), Cosentyx ($3.2 billion), and Kisqali ($2.1 billion).
Q3 REVENUES: Novartis reported performance for the first nine months of 2025, with total revenues reaching $41.2 billion, including $13.9 billion in the third quarter.
Entresto led with $6.5 billion in sales, Cosentyx generated $4.9 billion, while Kisqali delivered $3.5 billion reflecting expanding use in breast cancer. Kesimpta contributed $3.2 billion, highlighting sustained adoption in multiple sclerosis.
NOVO NORDISK
H1 REVENUES: Novo Nordisk reported revenues of $24.2 billion (DKK 154.9 billion) for the first half of 2025, marking a 16% increase in Danish kroner and 18% growth at constant exchange rates. Leading the company’s performance were Ozempic with $10 billion in sales and Wegovy with $5.7 billion.
SANOFI
H1 REVENUES: Sanofi reported revenues of $22.8 billion for the first half of 2025, with Dupixent continuing to lead the portfolio, generating $8.5 billion in sales.
Comments